Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia
Open Access
- 11 July 2006
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (3) , 401-405
- https://doi.org/10.1038/sj.bjc.6603246
Abstract
This study aimed to estimate the extent of ‘overdiagnosis’ of prostate cancer attributable to prostate-specific antigen (PSA) testing in the Cambridge area between 1996 and 2002. Overdiagnosis was defined conceptually as detection of prostate cancer through PSA testing that otherwise would not have been diagnosed within the patient's lifetime. Records of PSA tests in Addenbrookes Hospital were linked to prostate cancer registrations by NHS number. Differences in prostate cancer registration rates between those receiving and not receiving prediagnosis PSA tests were calculated. The proportion of men aged 40 years or over with a prediagnosis PSA test increased from 1.4 to 5.2% from 1996 to 2002. The rate of diagnosis of prostate cancer was 45% higher (rate ratios (RR)=1.45, 95% confidence intervals (CI) 1.02–2.07) in men with a history of prediagnosis PSA testing. Assuming average lead times of 5 to 10 years, 40–64% of the PSA-detected cases were estimated to be overdiagnosed. In East Anglia, from 1996 to 2000, a 1.6% excess of cases was associated with PSA testing (around a quarter of the 5.3% excess incidence cases observed in East Anglia from 1996 to 2000). Further quantification of the overdiagnosis will result from continued surveillance and from linkage of incidence to testing in other hospitals.Keywords
This publication has 16 references indexed in Scilit:
- Incidence trends of prostate cancer in East Anglia, before and during the era of PSA diagnostic testingBritish Journal of Cancer, 2006
- Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991–1994)European Journal Of Cancer, 2005
- Results of a randomized, population‐based study of biennial screening using serum prostate‐specific antigen measurement to detect prostate carcinomaCancer, 2004
- The Incidence of Prostate Cancer in Men With Prostate Specific Antigen Greater Than 4.0 Ng/Ml:: A Randomized Study Of 6 Versus 12 Core Transperineal Prostate BiopsyJournal of Urology, 2004
- Lead time associated with screening for prostate cancerInternational Journal of Cancer, 2003
- Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate CancerJNCI Journal of the National Cancer Institute, 2003
- Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence TrendsJNCI Journal of the National Cancer Institute, 2002
- Survey of the rate of PSA testing in general practiceBritish Journal of Cancer, 2001
- Would prostate cancer detected by screening withprostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in SwedenBJU International, 2000
- Screening for Prostate Cancer. Comparison of Transrectal Ultrasound, Prostate Specific Antigen and Rectal ExaminationBritish Journal of Urology, 1991